Compare HPP & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPP | DNA |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.9M | 562.3M |
| IPO Year | 2010 | N/A |
| Metric | HPP | DNA |
|---|---|---|
| Price | $12.52 | $9.54 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 12 | 1 |
| Target Price | ★ $19.89 | $9.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $781,676,000.00 | $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.08 | $7.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.69 | $5.00 |
| 52 Week High | $24.01 | $17.58 |
| Indicator | HPP | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 78.50 | 48.08 |
| Support Level | $12.91 | $8.56 |
| Resistance Level | $14.21 | $10.05 |
| Average True Range (ATR) | 0.55 | 0.55 |
| MACD | 0.67 | 0.28 |
| Stochastic Oscillator | 80.99 | 67.95 |
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.